On January 9, 2025, Numab Therapeutics AG closed the transaction. The company has amended the terms of the transaction. The company has received CHF 50 million in its second and final tranche bringing the total funding raised in the round to CHF 150 million.
The tranche waas co-led by returning investors Cormorant Asset Management, LP, Forbion Growth Opportunities Fund I, a fund managed by Forbion Capital Partners B.V., new fund HBM Healthcare Investments AG,a fund managed by HBM Partners Ltd., and Novo Holdings A/S. The transaction also included participation from returning investors BVF Partners L.P., Octagon Capital Advisors LP, RTW Investments, LP, and funds and accounts managed by BlackRock, Inc.